

COMMUNICATION

View Article Online
View Journal | View IssueCrossMark
click for updatesCite this: *RSC Adv.*, 2015, 5, 107119Received 24th September 2015
Accepted 7th December 2015

DOI: 10.1039/c5ra19790b

www.rsc.org/advances

Room-temperature palladium-catalysed Suzuki–Miyaura coupling of arylboronic acid with aryl chlorides†

Dan Wang,^{‡a} Hong-Guan Chen,^{‡a} Xin-Chuan Tian,^a Xiao-Xia Liang,^a
Feng-Zhen Chen^b and Feng Gao^{*a}

An efficient room-temperature Pd-catalyzed Suzuki–Miyaura cross-coupling reaction of aryl-boronic acids with aryl chlorides is communicated here. The Pd(OAc)₂/NiXantphos catalyst system enables the coupling reaction at room temperature in good to excellent yields (average yield >90%).

The construction of C–C bonds is considered to be an important issue in transition-metal catalyzed organic reactions.¹ With the discovery of the Suzuki–Miyaura cross-coupling of aryl-boronic acids with aryl halides in 1981,² a convenient and selective sp² C–C bond forming method was established.³ As boron is similar to carbon in size and electronegativity, both boronic acids and boronate esters are highly nucleophilic, and display excellent and broad functional group tolerance. In addition, structurally diverse biaryl motifs obtained from Suzuki reactions are important structural elements of a large number of natural products, pharmaceuticals, agrochemicals⁴ as well as many bioactive polymers.⁵ It is for these reasons that the Suzuki reaction has emerged as a favorite tool in both industrial and academic fields.


Although aryl chlorides have been proved to be inactive in Suzuki reaction since the very beginning, numerous low-cost compounds available in this class still attract many researchers' attention.⁶ To address this issue, high temperature (>100 °C), along with commercial metal/ligand, was generally employed in early protocols,⁷ which inevitably limited the substrate scope with heat-intolerant heterocyclic aryl halides, such as furans and thiophenes (Scheme 1A); later, to achieve room-temperature Suzuki coupling reaction with aryl chlorides, some novel ligands/pre-catalysts were successfully designed and prepared.⁸ However, these studies shared drawbacks like

difficult preparation procedures for the ligands/pre-catalysts (Scheme 1B). It is worth mentioning that some ligand-free researches were highlighted as they achieved room temperature Suzuki reactions in PEG. But unfortunately, they were all confined to phenyl-boronic acid.^{6,9} Therefore, it is still practically and theoretically significant to develop novel synthetic method for room-temperature Suzuki–Miyaura cross-coupling of aryl chlorides.

van Leeuwen's NiXantphos (see Scheme 1 for structure) has been proved to be an efficient ligand in sp³–sp² C–C formation by promoting several arylation reactions,¹⁰ yet its application in sp²–sp² has not been reported. In our preliminary work, we have disclosed the first direct 2-arylation of benzoxazoles catalyzed

Previous Works

A.




B.



This Works

C.



Scheme 1 Suzuki–Miyaura coupling of aryl chlorides.

^aDepartment of Chinese Traditional Herbal, Agronomy College, Sichuan Agricultural University, Chengdu 611130, P. R. China. E-mail: gaofeng@sicau.edu.cn^bSchool of Bioengineering, Chengdu University, Chengdu 610106, P. R. China


† Electronic supplementary information (ESI) available. See DOI: 10.1039/c5ra19790b

‡ D. W. and H. G. C. contributed equally.

by Pd/Nixantphos at room temperature.¹¹ Recently, Zhang reported that aryl chlorides could be activated by NiXantphos at room temperature.¹² So we surmised that NiXantphos might be active in room-temperature Suzuki cross coupling of aryl chlorides. Here, we are communicating an efficient Pd(OAc)₂/NiXantphos-catalyzed room-temperature Suzuki–Miyaura coupling of aryl-boronic acids with aryl chlorides (Scheme 1C).

Our research started from the screening of bases (KF, CsCO₃, K₂HPO₃, K₂CO₃, KHCO₃, KH₂PO₃), adopting Pd(OAc)₂/NiXantphos-based catalytic system with H₂O/THF (1 : 5) as solvent (Table 1). Results showed that with K₂CO₃ as base, 4-*tert*-butylphenylboronic acid **1a** (1.2 equiv.) and 1-chloro-4-methylbenzene **2a** (1.0 equiv.) could access to 4-*tert*-butyl-4'-methylbiphenyl **3a** in 88% yield after 3 h (Table 1, entry 3). And when the reaction time was prolonged to 6 h, the conversion rate was significantly improved. Then the scope of solvents (H₂O/THF, H₂O/PhH, H₂O/DME, H₂O/1,4-dioxane) were tested adopting K₂CO₃ as base at room temperature for 6 h. With H₂O/THF (1 : 5) as solvent, **3a** was afforded in near quantitative yield after 6 h (Table 1, entry 9).

The substrate scope of aryl chlorides **2a–n** (1.0 equiv.) with 4-*tert*-butylphenylboronic acid **1a** (1.2 equiv.) was investigated (Scheme 2) under the optimized reaction conditions as Pd(OAc)₂ (2 mol%), NiXantphos (3 mol%), K₂CO₃ (2.0 equiv.) in H₂O/THF (1 : 5) at room temperature for 6 h, and gave corresponding products **3a–n** in yields from 65% to 99%. In general, the reaction could be facilitated by strongly electron-withdrawing groups like tri-fluoromethyl, cyano group, nitro group, *etc.* (Scheme 2, **3e**, **3i**, **3j**, **3k**). As is shown in Scheme 2, heteroaryl compounds, mainly 2-phenylpyridines, account for half of the products. It is worth to mention that 2-phenylpyridine derivatives were widely reported to show antitumor and anticancer activity.¹³ Since our group has been conducting research on the design and synthesis of anti-cancer molecules



Scheme 2 Scope of aryl chloride in the room-temperature Suzuki coupling with 4-*tert*-butylphenylboronic acid (**1a**).

with simple structures,¹⁴ 2-chloro pyridines were preferred substrates in this work.

2-Phenyl-5-(tri-fluoromethyl) pyridine derivatives were reported to have various bioactivities,¹⁵ like g-secretase modulation, antimalarial activity, P2X3 receptor antagonism, glucagon receptor antagonism, *etc.* Therefore, it was chosen in the scope investigations of aryl-boronic acids **1b–o** (1.2 equiv.) (Scheme 3) under the optimized reaction conditions as Pd(OAc)₂ (2 mol%), NiXantphos (3 mol%), K₂CO₃ (2 equiv.) in H₂O/THF (1 : 5) at room temperature for 6 h, and gave corresponding products **4a–n** in yields from 70% to 96%. It could be seen that the reaction could be suppressed when possessing substrates with strongly electron-donating groups like ether group (Scheme 3, **4e**). Among the coupling products, **4m** and **4n** were afforded from 2-furanboronic acid **1n** and 2-thiophenylboronic acid **1o** with **2k**, respectively, proving the successful application of heteroarylboronic acids.


Para, *meta* and *ortho* substituents in aryl chlorides were all well tolerated in the room-temperature Suzuki coupling with 4-*tert*-butylphenylboronic acid, providing products in yields from 65% to 99%. Similarly, *para* and *meta* substituents in aryl boronic acids were well tolerable, and afforded products in yields from 70% to 96%.

We also evaluated the scalability of this method by performing the coupling of 3-chloropyridine **2m** with 4-methoxyphenylboronic acid **1f** on gram scale (Scheme 4). The coupling product, 3-(4-methoxyphenyl)pyridine **5a** was isolated in 60% yield. This yield is relatively high, proving that the Pd(OAc)₂/NiXantphos based catalyst could stay active in room-temperature


Table 1 Optimization of Suzuki coupling of 4-*tert*-butylphenylboronic acid (**1a**) with 1-chloro-4-methylbenzene (**2a**)^a

Entry	Base	Solvent (ratio)	Time	Yield ^b (%)
1	KF	H ₂ O/THF (1 : 5)	3 h	58
2	CsCO ₃	H ₂ O/THF (1 : 5)	3 h	55
3	K ₂ CO ₃	H ₂ O/THF (1 : 5)	3 h	88
4	KF	H ₂ O/THF (1 : 5)	6 h	60
5	CsCO ₃	H ₂ O/THF (1 : 5)	6 h	80
6	K ₂ HPO ₃	H ₂ O/THF (1 : 5)	6 h	85
7	KHCO ₃	H ₂ O/THF (1 : 5)	6 h	90
8	KH ₂ PO ₃	H ₂ O/THF (1 : 5)	6 h	90
9	K ₂ CO ₃	H ₂ O/THF (1 : 5)	6 h	95
10	K ₂ CO ₃	H ₂ O/PhH (1 : 5)	6 h	75
11	K ₂ CO ₃	H ₂ O/DME (1 : 5)	6 h	92
12	K ₂ CO ₃	H ₂ O/dioxane (1 : 5)	6 h	90

^a Reactions performed using 1.2 equiv. of **1a**, 1.0 equiv. of **2a** and 2.0 equiv. of base on a 0.2 mmol scale. ^b Isolated yields.



Scheme 3 Scope of aryl boronic acid in the room-temperature Suzuki coupling with 2-chloro-5-(trifluoromethyl) pyridine (2k).



Scheme 4 Room-temperature Suzuki coupling of 3-chloropyridine with 4-methoxyphenylboronic acid on gram scale.

Suzuki cross coupling of aryl chlorides without chelating with nitrogen atom in pyridine.

In summary, $\text{Pd}(\text{OAc})_2/\text{NiXantphos}$ -catalyzed Suzuki–Miyaura cross-coupling reaction of aryl-boronic acids with aryl chlorides were realized at room temperature in high yields (average yield >90%). In our method, a broad range of substrates could be adopted to afford diverse products with minor limitations. The success of this method attributes to the application of commercially available ligand NiXantphos. Next, we will continue our exploration for cross coupling reaction of aryl chlorides using NiXantphos as ligand.

Acknowledgements

We thank the NSFC (no. 31570341) and Key Technology Support Program of Scihuan Provice, China (no. 2015SZ0105) for financial support.

Notes and references

- 1 K. Sambasivarao, L. Kakali and K. Dhurke, *Tetrahedron*, 2002, **58**, 9633.

- 2 N. Miyaura, T. Yanagi and A. Suzuki, *Synth. Commun.*, 1981, **11**, 513.
- 3 (a) K. C. Nicolaou, P. G. Bulger and D. Sarlah, *Angew. Chem., Int. Ed.*, 2005, **44**, 4442; (b) C. You, P. Hui, Y. X. Pi, T. Meng, Z. Y. Lian, M. Q. Yan, Y. Liu, S. H. Liu and G. A. Yu, *Org. Biomol. Chem.*, 2015, **13**, 3236.
- 4 (a) A. Suzuki, *J. Org. Chem.*, 1999, **576**, 147; (b) L. A. Thompson and J. A. Ellman, *Chem. Rev.*, 1996, **96**, 555; (c) S. P. Stanforth, *Tetrahedron*, 1998, **54**, 263; (d) M. C. Kozlowski, B. J. Morgan and E. C. Linton, *Chem. Soc. Rev.*, 2009, **38**, 3193.
- 5 (a) D. A. Horton, G. T. Bourne and M. L. Smythe, *Chem. Rev.*, 2003, **103**, 893; (b) T. Guo, A. E. P. Adang, R. E. Dolle, G. Dong, D. Fitzpatrick, P. Geng, K. K. Ho, S. G. Kultgen, R. Liu, E. McDonald, B. F. McGuinness, K. W. Saionz, K. J. Valenzano, N. C. R. van Straten, D. Xie and M. L. Webb, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 1713; (c) R. Faghih, W. Dwight, J. B. Pan, G. B. Fox, K. M. Krueger, T. A. Esbenschade, J. M. McVey, K. Marsh, Y. L. Bennani and A. A. Hancock, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 1325; (d) E. A. Jefferson, P. P. Seth, D. E. Robinson, D. K. Winter, A. Miyaji, L. M. Risen, S. A. Osgood, M. Bertrand and E. E. Swayze, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 5257; (e) G. T. Wang, S. Wang, R. Gentles, T. Sowin, S. Leitza, E. B. Reilly and T. W. von Geldern, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 195.
- 6 L. Yin, Z. Zhang and Y. Wang, *Tetrahedron*, 2006, **62**, 9359.
- 7 (a) M. B. Mitchell and P. J. Wallbank, *Tetrahedron Lett.*, 1991, **32**, 2273; (b) W. Shen, *Tetrahedron Lett.*, 1997, **38**, 5575; (c) A. F. Littke and G. C. Fu, *Angew. Chem., Int. Ed.*, 1998, **37**, 3387; (d) A. Zapf and M. Beller, *Chem.-Eur. J.*, 2000, **6**, 1830; (e) A. Zapf, A. Ehrentraut and M. Beller, *Angew. Chem., Int. Ed.*, 2000, **39**, 4153; (f) J. H. Li and W. J. Liu, *Org. Lett.*, 2004, **6**, 2809; (g) R. K. Arvela and N. E. Leadbeater, *Org. Lett.*, 2005, **7**, 2101.
- 8 (a) L. Botella and C. Nájera, *Angew. Chem., Int. Ed.*, 2002, **41**, 179; (b) C. W. K. Gstöttmayr, V. P. W. Böhm, E. Herdtweck, M. Grosche and W. A. Herrmann, *Angew. Chem., Int. Ed.*, 2002, **41**, 1363; (c) O. Navarro, R. A. Kelly and S. P. Nolan, *J. Am. Chem. Soc.*, 2003, **125**, 16194; (d) N. Marion, O. Navarro, J. Mei, E. D. Stevens, N. M. Scott and S. P. Nolan, *J. Am. Chem. Soc.*, 2006, **128**, 4101; (e) T. Kinzel, Y. Zhang and S. L. Buchwald, *J. Am. Chem. Soc.*, 2010, **132**, 14073; (f) M. T. Chen, D. A. Vicic, M. L. Turner and O. Navarro, *Organometallics*, 2011, **30**, 5052; (g) F. Rajabi and W. R. Thiel, *Adv. Synth. Catal.*, 2014, **356**, 1873; (h) J.-Y. Lee, D. Ghosh, J.-Y. Lee, S.-S. Wu, C.-H. Hu, S.-D. Liu and H. M. Lee, *Organometallics*, 2014, **33**, 6481; (i) R. Ghosh, N. N. Adarsh and A. Sarkar, *J. Org. Chem.*, 2010, **75**, 5320; (j) T. E. Barder, S. D. Walker, J. R. Martinelli and S. L. Buchwald, *J. Am. Chem. Soc.*, 2005, **127**, 4685; (k) D. Liu, W. Gao, Q. Dai and X. Zhang, *Org. Lett.*, 2005, **7**, 4907; (l) C. M. So, C. C. Yeung, C. P. Lau and F. Y. Kwong, *J. Org. Chem.*, 2008, **73**, 7803; (m) S. R. Dubbaka and P. Vogel, *Org. Lett.*, 2004, **6**, 95; (n) D. W. Old, J. P. Wolfe and S. L. Buchwald, *J. Am. Chem. Soc.*, 1998, **120**, 9722; (o) A. Konovets, A. Penciu, E. Framery, N. Percina, C. G. Henry

- and D. Sinou, *Tetrahedron Lett.*, 2005, **46**, 3205; (p) M. Ueda, M. Nishimura and N. Miyaura, *Synlett*, 2000, 0856; (q) C. Zhang, J. Huang, M. L. Trudell and S. P. Nolan, *J. Org. Chem.*, 1999, **64**, 3804–3805; (r) A. Kumar, G. K. Rao, F. Saleem, R. Kumar and A. K. Singh, *J. Hazard. Mater.*, 2014, **269**, 9; (s) S. Li, Y. Lin, J. Cao and S. Zhang, *J. Org. Chem.*, 2007, **72**, 4067; (t) G. A. Molander and B. Biolatto, *J. Org. Chem.*, 2003, **68**, 4302; (u) X. Bei, H. W. Turner, W. H. Weinberg and A. S. Guram, *J. Org. Chem.*, 1999, **64**, 6797; (v) K. W. Anderson and S. L. Buchwald, *Angew. Chem., Int. Ed.*, 2005, **44**, 6173; (w) K. L. Billingsley, K. W. Anderson and S. L. Buchwald, *Angew. Chem., Int. Ed.*, 2006, **45**, 3484.
- 9 (a) W. H. Han, C. Liu and Z. L. Jin, *Org. Lett.*, 2007, **9**, 4005; (b) W. H. Han, C. Liu and Z. L. Jin, *Adv. Synth. Catal.*, 2008, **350**, 501.
- 10 (a) T. Jia, A. Bellomo, K. E. L. Baina, S. D. Dreher and P. J. Walsh, *J. Am. Chem. Soc.*, 2013, **135**, 3740; (b) J. Zhang, A. Bellomo, A. D. Creamer, S. D. Dreher and P. J. Walsh, *J. Am. Chem. Soc.*, 2012, **134**, 13765; (c) S.-C. Sha, J. Zhang, P. J. Carroll and P. J. Walsh, *J. Am. Chem. Soc.*, 2013, **135**, 17602; (d) A. Bellomo, J. Zhang, N. Trongsiriwata and P. J. Walsh, *Chem. Sci.*, 2013, **4**, 849; (e) M. Li, B. Yücel, J. Adrio, A. Bellomo and P. J. Walsh, *Chem. Sci.*, 2014, **5**, 2383.
- 11 F. Gao, B. S. Kim and P. J. Walsh, *Chem. Commun.*, 2014, **50**, 10661.
- 12 J. Zhang, A. Bellomo, N. Trongsiriwat, T. Jia, P. J. Carroll, S. D. Dreher, M. T. Tudge, H. Yin, J. R. Robinson, E. J. Schelter and P. J. Walsh, *J. Am. Chem. Soc.*, 2014, **136**, 6276.
- 13 (a) R. Cao, J. Jia, X. Ma, M. Zhou and H. Fei, *J. Med. Chem.*, 2013, **56**, 3636; (b) C. Gabbiani and L. Messori, *Anti-Cancer Agents Med. Chem.*, 2011, **11**, 929; (c) S. F. Ralph, *Curr. Top. Med. Chem.*, 2011, **11**, 572; (d) D. Fan, C. T. Yang, J. D. Ranford, J. J. Vittal and P. F. Lee, *Dalton Trans.*, 2003, **17**, 3376.
- 14 X.-X. Chen, F. Gao, Q. Wang, X. Huang and D. Wang, *Fitoterapia*, 2014, **92**, 111.
- 15 (a) S. Sato, S. Matsuda, C. Matsumura, M. Itotani, T. Shinohara, S. Fujita, Y. Sakurai, K. Tai, T. Fukushima, N. Kanemoto and T. Okamoto, WO2015/8872 A1, 2015; (b) G. D. Heffernan, D. P. Jacobus, K. W. Saionz, G. A. Schiehser, H.-M. Shieh and W. Zhao, US2014/135320 A1, 2014; (c) M. Mori, K. Fujii, M. Inui, T. Baba, Y. Onishi and A. Aoyagi, EP2700643 A1, 2014; (d) M. Mori, K. Fujii, M. Inui, T. Baba, Y. Onishi and A. Aoyagi, WO2012/144478 A1, 2012; (e) C. S. Burgey, Z. J. Deng, D. N. Nguyen, D. V. Paone, C. M. Potteiger and J. P. Vacca, WO2009/058298 A1, 2009; (f) C. Y. Ho, WO2009/052341 A1, 2009; (g) R. M. Kim, E. R. Parmee, Q. Tan, A. R. Lins, J. Chang and C.-M. Yang, WO2007/111864 A2, 2007.